Our study demonstrates that LGR5 can serve as a functional GSC marker, drive GSCs EMT and by activating the Wnt/β-catenin pathway in vitro and in vivo, and predicts glioma recurrence and poor prognosis. The gene discussed is LGR5; the disease is central nervous system cancer.